Primary cutaneous follicle centre lymphoma medical therapy
|
Primary cutaneous follicle centre lymphoma Microchapters |
|
Differentiating Primary cutaneous follicle centre lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Primary cutaneous follicle centre lymphoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Primary cutaneous follicle centre lymphoma medical therapy |
|
FDA on Primary cutaneous follicle centre lymphoma medical therapy |
|
CDC on Primary cutaneous follicle centre lymphoma medical therapy |
|
Primary cutaneous follicle centre lymphoma medical therapy in the news |
|
Blogs on Primary cutaneous follicle centre lymphoma medical therapy |
|
Directions to Hospitals Treating Splenic marginal zone lymphoma |
|
Risk calculators and risk factors for Primary cutaneous follicle centre lymphoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overvew
The predominant therapy for primary cutaneous follicle centre lymphoma is radiotherapy. Adjunctive chemotherapy may be required.
Medical Therapy
- Surgical removal and/or radiotherapy is given for localized disease.[1][2]
- Radiation using multiple radiation fields is given if the disease has wider extent with grouped lesions.[1]:314[3][4][2]
- For the less common situation of more extensive disease (still confined to skin), rituximab without chemotherapy is used.[1][3][4][2]Intralesional interferon alpha (IFN-α)[5]and intralesional rituximab have been used.[1][5]
- There are mixed results of CHOP and R-CHOP. In one study on 104 patients CHOP chemotherapy demonstrated complete responses in 85 percent of the patients.[6]
- There are also published case reports presented clinical responses to topical class 1 corticosteroids.[7]
- Approximately one-third of primary cutaneous follicle centre lymphoma relapse, usually in the skin; treatment is similar to initial management[2] and overall survival remains excellent.[8]
References
- ↑ 1.0 1.1 1.2 1.3 Jaffe, ES (2011). Hematopathology (1st ed.). Elsevier Saunders. ISBN 9780721600406. Unknown parameter
|coauthors=ignored (help) - ↑ 2.0 2.1 2.2 2.3 Wilcox RA (2015). "Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management". Am. J. Hematol. 90 (1): 73–6. doi:10.1002/ajh.23863. PMID 25535037.
- ↑ 3.0 3.1 Armitage, JO; Mauch PM; Harris NL; et al. (2010). "Chapter 24". Non-Hodgkin Lymphomas (2nd ed.). Lippincott Williams & Wilkins. ISBN 9780781791168.
- ↑ 4.0 4.1 Sokol L, Naghashpour M, Glass LF (2012). "Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management". Cancer Control. 19 (3): 236–44. PMID 22710899.
- ↑ 5.0 5.1 Senff NJ, Noordijk EM, Kim YH, et al. (2008). "European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas". Blood. 112 (5): 1600–9. doi:10.1182/blood-2008-04-152850. PMID 18567836.
- ↑ Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L; et al. (2008). "European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas". Blood. 112 (5): 1600–9. doi:10.1182/blood-2008-04-152850. PMID 18567836.
- ↑ Suárez AL, Querfeld C, Horwitz S, Pulitzer M, Moskowitz A, Myskowski PL (2013). "Primary cutaneous B-cell lymphomas: part II. Therapy and future directions". J Am Acad Dermatol. 69 (3): 343.e1–11, quiz 355-6. doi:10.1016/j.jaad.2013.06.011. PMID 23957985.
- ↑ Suárez AL, Querfeld C, Horwitz S, et al. (2013). "Primary cutaneous B-cell lymphomas: part II. Therapy and future directions". J. Am. Acad. Dermatol. 69 (3): 343.e1–11, quiz 355–6. doi:10.1016/j.jaad.2013.06.011. PMID 23957985.